The effectiveness of low-dose naltrexone as a medical treatment is contested, with some reviews and studies suggesting potential benefits for chronic pain and inflammatory conditions, while recent meta-analyses and controlled trials indicate that its effects may not significantly outperform placebos or standard treatments, with high discontinuation rates.
The evidence we hold leans leans supported
official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x
The retrieved papers present mixed findings. Several reviews and observational reports (e.g., [0], [4], [9], [10]) highlight potential benefits, mechanisms, and off-label utility of low-dose naltrexone (LDN) for conditions like fibromyalgia and dermatologic disorders. Conversely, rigorous studies and meta-analyses challenge its effectiveness: a clinical trial ([3]) found LDN no better than placebo/standard treatment, a cohort study ([6]) noted high discontinuation rates due to lack of benefit despite a minor statistical change in scores, and a meta-analysis ([8]) concluded that LDN was not superior to placebo for fibromyalgia. Because high-quality syntheses and trials conflict with the positive clinical reports, the verdict is CONTESTED.